脑铁沉积、外周铁过载与认知功能障碍研究进展
Brain Iron Deposition, Body Iron Overload and Cognitive Impairment
作者: 汪 昕 :复旦大学附属中山医院神经内科,上海;复旦大学脑科学研究院神经生物学国家重点实验室,上海;
关键词: 脑铁沉积; 铁过载; 认知功能障碍; Brain Iron Deposition; Body Iron Overload; Cognitive Impairment
摘要:文章引用: 汪 昕 (2013) 脑铁沉积、外周铁过载与认知功能障碍研究进展。 生理学研究, 1, 16-19. doi: 10.12677/JPS.2013.13004
参考文献
[1] S. Grantham-McGregor, C. Ani. A review of studies on the effect of iron deficiency on cognitive development in children. Journal of Nutrition, 2001, 131(2S-2): 649S-666S.
[2] W. M. Mohamed, et al. Methylphenidate improves cognitive deficits produced by infantile iron deficiency in rats. Behavioural Brain Research, 2011, 216(1): 146-152.
[3] M. B. Youdim. Brain iron deficiency and excess; cognitive impairment and neurodegeneration with involvement of striatum and hippocampus. Neurotoxicity Research, 2008, 14(1): 45-56.
[4] J. M. Pearce. Neurodegeneration with brain iron accumulation: A cautionary tale. European Neurology, 2006, 56(1): 66-68.
[5] A. F. Santillo, et al. Frontotemporal dementia-amyotrophic lateral sclerosis complex is simulated by neurodegeneration with brain iron accumulation. Alzheimer Disease and Associated Disorders, 2009, 23(3): 298-300.
[6] J. Y. Liu, et al. T2* MRI of minimal hepatic encephalopathy and cognitive correlates in vivo. Journal of Magnetic Resonance Imaging, 2013, 37(1): 179-186.
[7] S. C. Eng, et al. Hepatic iron overload in alcoholic end-stage liver disease is associated with iron deposition in other organs in the absence of HFE-1 hemochromatosis. Liver International, 2005, 25(3): 513-517.
[8] D. Lin, et al. Decreased Serum Hepcidin Concentration Correlates with Brain Iron Deposition in Patients with HBV-Related Cirrhosis. PLoS One, 2013, 8(6): e65551.
[9] W. Z. Zhu, et al. Quantitative MR phase-corrected imaging to investigate increased brain iron deposition of patients with Alzheimer disease. Radiology, 2009, 253(2): 497-504.
[10] B. Ding, et al. Correlation of iron in the hippocampus with MMSE in patients with Alzheimer’s disease. Journal of Magnetic Resonance Imaging, 2009, 29(4): 793-798.
[11] S. Haller, et al. Cerebral microhemorrhage and iron deposition in mild cognitive impairment: susceptibility-weighted MR imaging assessment. Radiology, 2010, 257(3): 764-773.
[12] M. A. Smith, et al. Increased iron and free radical generation in preclinical Alzheimer disease and mild cognitive impairment. Journal of Alzheimer’s Disease, 2010, 19(1): 363-372.
[13] W. Kirsch, et al. Serial susceptibility weighted MRI measures brain iron and microbleeds in dementia. Journal of Alzheimer’s Disease, 2009, 17(3): 599-609.
[14] E. V. Sullivan, et al. Relevance of Iron Deposition in Deep Gray Matter Brain Structures to Cognitive and Motor Performance in Healthy Elderly Men and Women: Exploratory Findings. Brain Imaging and Behavior, 2009, 3(2): 167-175.
[15] P. K. Lam, et al. Plasma trace elements and cognitive function in older men and women: the Rancho Bernardo study. The Journal of Nutrition Health and Aging, 2008, 12(1): 22-27.
[16] O. J. Schiepers, et al. Serum iron parameters, HFE C282Y geno- type, and cognitive performance in older adults: Results from the FACIT study. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences, 2010, 65(12): 1312-1321.
[17] E. A. Milward, et al. A cross-sectional community study of serum iron measures and cognitive status in older adults. Journal of Alzheimer’s Disease, 2010, 20(2): 617-623.
[18] S. A. Mandel, et al. Simultaneous manipulation of multiple brain targets by green tea catechins: A potential neuroprotective strategy for Alzheimer and Parkinson diseases. CNS Neuroscience & Therapeutics, 2008, 14(4): 352-365.
[19] S. A. Mandel, et al. Cell signaling pathways and iron chelation in the neurorestorative activity of green tea polyphenols: Special reference to epigallocatechin gallate (EGCG). Journal of Alzheimer’s Disease, 2008, 15(2): 211-222.
[20] S. Mandel, et al. Iron dysregulation in Alzheimer’s disease: Mul- timodal brain permeable iron chelating drugs, possessing neuroprotective-neurorescue and amyloid precursor protein-proces- sing regulatory activities as therapeutic agents. Progress in Neurobiology, 2007, 82(6): 348-360.
[21] M. D. Crapper, et al. Intramuscular desferrioxamine in patients with Alzheimer’s disease. Lancet, 1991, 337(8753): 1304-1308.
[22] C. W. Ritchie, et al. Metal-protein attenuation with iodochlorhy-droxyquin (clioquinol) targeting A beta amyloid deposition and toxicity in Alzheimer disease—A pilot phase 2 clinical trial. Archives of Neurology, 2003, 60(12): 1685-1691.